home / stock / jbio / jbio news

JBIO News and Press, Jade Biosciences Inc. From 11/08/25

Stock Information
Company Name: Jade Biosciences Inc.
Stock Symbol: JBIO
Market: NASDAQ
Website: jadebiosciences.com/
Menu
JBIO JBIO Quote JBIO Short JBIO News JBIO Articles JBIO Message Board
Get JBIO Alerts

News, Short Squeeze, Breakout and More Instantly...
JBIO - Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025

SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today presen...
JBIO - Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025

Presentations to highlight JADE101’s preclinical safety profile and translational framework guiding its clinical development in IgA nephropathy JADE101 is an investigational, potentially best-in-class disease-modifying anti-APRIL monoclonal antibody, with a Phase 1 health...

JBIO - Jade Biosciences offers $135 million equity through private placement

2025-10-07 07:19:22 ET More on Jade Biosciences, Inc. Jade Biosciences, Inc. GAAP EPS of -$0.86 Historical earnings data for Jade Biosciences, Inc. Dividend scorecard for Jade Biosciences, Inc. Financial information for Jade Biosciences, Inc. Read t...

JBIO - Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases

JADE201 builds on clinical proof-of-concept for BAFF-R targeting, adding half-life extension technology to provide extended receptor occupancy with the goal of delivering deeper, more durable B cell depletion with less frequent subcutaneous dosing JADE201’s high affinity binding ...
JBIO - Jade Biosciences Announces $135 Million Private Placement

SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announ...

JBIO - Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy

Selective APRIL inhibition has shown disease-modifying potential in IgAN patient clinical trials JADE101 has shown ultra-high binding affinity and a differentiated pharmacokinetic and pharmacodynamic profile preclinically, supporting the potential for patient-friendly subcutaneous dosing ...

JBIO - Jade Biosciences to Participate in Upcoming Conferences

SAN FRANCISCO and VANCOUVER, British Columbia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the following upcomin...
JBIO - Jade Biosciences, Inc. GAAP EPS of -$0.86

2025-08-13 17:10:08 ET More on Jade Biosciences, Inc. Historical earnings data for Jade Biosciences, Inc. Dividend scorecard for Jade Biosciences, Inc. Financial information for Jade Biosciences, Inc. Read the full article on Seeking Alpha For further...

JBIO - Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Presented preclinical data for JADE101 at the 62nd European Renal Association Congress, highlighting its potential as a best-in-class anti-APRIL monoclonal antibody for IgA nephropathy Phase 1 healthy-volunteer study of JADE101 expected to begin in the third quarter of 2025, with inte...

JBIO - Expected US Company Earnings on Monday, August 11th, 2025

Xenon Pharmaceuticals Inc. (XENE) is expected to report $-1.03 for Q2 2025 Gaia Inc. (GAIA) is expected to report $-0.08 for Q2 2025 Insight Molecular Diagnostics Inc. (IMDX) is expected to report for Q2 2025 Lightbridge Corporation (LTBR) is expected to report for Q2 2025 NewHold...
Previous 10 Next 10